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Abstract—Non-motor symptoms, such as fear of falling and
anxiety, are frequently reported in Parkinson’s disease (PD).
Recent evidence of anxiety and fear directly influencing bal-
ance control in healthy young and older adults, raises the
question whether fear of falling and anxiety also directly
contribute to the balance deficits observed in PD. The goal of
the current study was to examine whether PD patients and
controls responded similarly or differently to experimentally
induced increases in anxiety. For this purpose, 14 PD pa-
tients (tested during a subjective optimal ON state) and 16
healthy age-matched control subjects stood in three condi-
tions of different levels of postural threat: normal threat
(quiet standing at ground level); medium threat (standing at
the edge of a surface elevated to 80 cm); and high threat
(same, but to 160 cm). Outcome measures included mean
position, mean power of frequency (MPF) and root mean
square (RMS) of centre of pressure (COP) displacements in
the anterior-posterior (AP) and medial-lateral (ML) directions.
Physiological and psychosocial measures of fear and anxiety
were also recorded. Increased threat changed postural con-
trol similarly in PD patients and controls; MPF of AP and ML
COP increased and the mean COP position was shifted back-
ward in both groups. These results indicate that during the
ON state, static balance in PD patients and controls is equally
susceptible to the influence of anxiety. Significant correla-
tions observed between COP changes and measures of fear
and anxiety provide evidence to support the proposed neural
links between structures controlling emotion and postural
control. Future studies should further address this issue by
including more severely affected patients, by testing the in-
fluence of dopaminergic medication, by including more anx-
ious patients, and by using dynamic measures of balance.
© 2011 IBRO. Published by Elsevier Ltd.
Key words: Parkinson’s disease, balance, postural control,
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Postural instability is a particularly disabling symptom in
Parkinson’s disease (PD) as it frequently leads to falls and
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MSE, mini mental state examination; MPF, mean power of fre-
uency; PANAS-X, positive and negative affect schedule– expanded
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Open access under the Elsevier OA injuries (Koller et al., 1989; Bloem et al., 2001). Medical
management of postural instability remains difficult (Bloem
and Bhatia, 2004), and development of improved therapies
is hampered by lack of adequate pathophysiological in-
sights. Careful assessment of the characteristics of pos-
tural control in PD is therefore a major issue for this patient
population, as this provides the basis for rational develop-
ment of improved treatment strategies tailored to specific
contributing factors.
One way in which postural control is assessed in PD is
to measure the characteristics of postural sway during
periods of quiet stance. Sway is typically assessed by
having subjects stand quietly on a forceplate, which re-
cords ground-reaction forces and moments that can be
used to calculate the centre of pressure (COP), a weighted
average of all forces acting beneath the feet (Winter et al.,
1996). The COP is considered the primary control variable
responsible for restricting natural sway of the body’s centre
of mass (COM) and thus maintain equilibrium. The char-
acteristics of the COP signal are usually quantified in terms
of its mean position, amplitude and frequency of displace-
ments in the anterior-posterior (AP) and medial-lateral
(ML) directions, which are known to be controlled indepen-
dently by the CNS (Winter et al., 1996). Amplitude and
frequency measures are used to describe the oscillatory
nature of the COP signal which reflects the net neuromus-
cular response of the CNS to control the COM. Mean
position of the COP reflects the average vertical projection
of the COM during stance and therefore provides an indi-
rect measure of leaning during stance.
While a number of prior studies have measured the
characteristics of postural sway to investigate quiet stand-
ing performance in PD, the results have been inconsistent.
For example, during quiet standing some investigators
observed PD patients to have larger amplitudes of postural
sway compared to age-matched controls (Mitchell et al.,
1995; Contin et al., 1996; Rocchi et al., 2002; Maurer et al.,
2003; Nardone and Schieppati, 2006; Błaszczyk et al., 2007);
some have found no difference between the groups (Schiep-
pati and Nardone, 1991; Termoz et al., 2008); while another
found smaller postural sway in PD patients (Horak et al.,
1992). While studies have shown the frequency (or veloc-
ity) of COP displacements to be higher in PD patients
compared to elderly controls (Rocchi et al., 2002; Maurer
et al., 2003), the changes in mean position are more
variable; some studies have reported a forward shift in
mean COP position in PD patients compared to elderly
controls (Błaszczyk et al., 2007; Termoz et al., 2008), while
another has reported a more backward shift of mean COP
in PD patients (Schieppati and Nardone, 1991).
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E. P. Pasman et al. / Neuroscience 177 (2011) 283–291284The potential origins of balance deficits in PD also
emain largely unclear. Traditionally postural deficits have
een attributed to disrupted dopaminergic pathways in the
asal ganglia specifically responsible for processing motor
ommands. However, evidence is beginning to suggest
hat balance problems may not be solely attributable to the
esult of motor processing deficits in PD (Wright et al.,
010; Beckley et al., 1993; Brown et al., 2007). Further-
ore, while pharmacological and surgical treatments are
ighly successful in alleviating motor symptoms such as
radykinesia, stiffness and tremor, they often provide little
o no improvement to postural control during quiet stance
Rocchi et al., 2002; Bloem and Bhatia, 2004; Bloem et al.,
996). As such, attention has now started to shift to con-
ider other non-motor functions within the basal ganglia as
ossible contributors to the development of postural defi-
its in PD.
Of the basal ganglia’s non-motor functions, its role in
motional processing, has received the least consideration
s a possible contributor to postural control. One of five
arallel circuits within the basal ganglia, the limbic circuit is
hought to be involved in higher-order processing of emo-
ional information, and acts as a gate for widespread
ources of emotional cues. Emotion is also commonly
ffected by PD. For example, between 28% and 38% of
D patients are diagnosed with clinical anxiety disorders
ccording to Diagnostic and Statistical Manual of Mental
isorders III-R criteria (Stein et al., 1990; Menza et al.,
993). Non-clinical anxiety is found in 20–69% of PD
atients (Aarsland et al., 1999; Kulisevsky et al., 2008),
hile up to 45% of PD patients have a fear of falling (Bloem
t al., 2001). These rates are significantly higher than
hose reported for healthy elderly persons (Lyketsos et al.,
000; Bloem et al., 2001; Ritchie et al., 2004; Trollor et al.,
007; Geda et al., 2008). Furthermore, PD patients have
eficits in generating normal physiological and cortical re-
ponses to emotional or threatening stimuli (Yoshimura et
l., 2005; Bowers et al., 2006; Tessitore et al., 2002).
Interconnections between limbic and motor control cir-
uitry within the basal ganglia, provide the means for the
NS to shape motor outputs based on the emotional con-
ext or meaning of a situation (Nakano, 2000), and may
xplain the relationship observed between anxiety and
otor symptom severity in patients with PD (Routh et al.,
987). However, the question remains whether dysregula-
ion of emotions, such as fear and anxiety, can also con-
ribute to postural deficits associated with PD. The poten-
ial for anxiety to directly influence postural control has
een recently demonstrated in healthy individuals. For
xample, studies have used elevated surface heights to
irectly investigate the effect of fear and anxiety on pos-
ural control in healthy young and older adult populations.
he results of these studies suggest that standing on an
ncreased surface height leads to changes in postural con-
rol, including a decrease of the amplitude and an increase
f the frequency of AP COP displacements, as well as a
ackward displacement of the mean COP position (Car-
enter et al., 1999, 2001a, 2006; Adkin et al., 2000; Brown
t al., 2006). Whether such mechanisms are also at play inD is much less clear. One study found that PD patients do
ot employ the same postural strategies as healthy con-
rols when standing at or away from the edge of an ele-
ated surface (Brown et al., 2007). However, this study
ad several possible drawbacks: standing was measured
or only very short time periods (15 s); changes in anxiety
nd fear were not verified experimentally; and it was step
estriction as opposed to surface height that was used to
anipulate postural threat.
Therefore, the aim of this study was to examine
hether PD patients and controls would respond similarly
o increases in postural threat. Based on earlier work
Brown et al., 2007), we hypothesized that PD patients
ould not utilize the same postural strategies as healthy
ontrols when standing on elevated surface heights.
EXPERIMENTAL PROCEDURES
Participants
Fourteen subjects with PD and 16 healthy age-matched control
subjects participated in the study (Tables 1 and 2). Each participant
provided written informed consent prior to testing. The Hoehn and
Yahr scale and motor examination subscale of the unified Parkin-
son’s disease rating scale (UPDRS) were used to assess the severity
of motor symptoms in PD patients. All participants completed a fall
history andmedical history survey, the mini mental state examination
(MMSE) (Folstein et al., 1975), and the frontal assessment battery
(Dubois et al., 2000). Because medication generally has little effect
on postural control during quiet stance (Rocchi et al., 2002; Bloem
and Bhatia, 2004; Bloem et al., 1996), all PD patients were examined
during their subjectively best ON clinical condition. Testing was timed
to coincide with the expected time of each patient’s subjectively best
clinical condition, approximately 1 h after intake of their regular Par-
kinson medication (Tables 1 and 2). Participants were excluded if
hey had a medical condition other than PD that interfered with their
alance, or had an MMSE score 24. Subjects were also excluded
f they had an extreme fear of heights, a history of anxiety disorders
r were taking any anti-anxiety medications. PD patients were ex-
luded if they had a neurosurgical procedure for their PD, or when
eurological examinations showed considerable postural tremor or
ignificant dyskinesias that would influence the COP recordings. All
xperimental procedures were approved by the UBC Clinical Re-
earch Ethics Board.
Procedures
Subjects stood quietly in stocking feet on a forceplate (model
#k00407, Bertec, USA) covered by a non-compliant rubber mat (0.5
cm thick) for a period of 120 s in four different conditions. The first
condition was standing on ground level (normal condition), with the
top surface of the forceplate located 9 cm above the ground. The
second was a reduced threat condition which involved standing on
ground level with additional safety features in place. However, this
condition failed to elicit desired effects on reducing anxiety and
increasing confidence in either group and was thus excluded from
further analysis. The third condition was standing at the edge of a
hydraulic platform elevated 80 cm above the ground (medium threat
condition). The fourth was standing at the edge of the hydraulic
platform elevated 160 cm above the ground (high threat condition).
To ensure the safety of participants during the trials on the hydraulic
platform, participants wore a safety harness which was securely
fastened with rope to a support beam in a manner that did not
interfere with their postural control. In all conditions a spotter stood
behind the participants during the trial. The participants stood with
their eyes open, arms hanging loosely by their sides and feet placed
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E. P. Pasman et al. / Neuroscience 177 (2011) 283–291 285shoulder width apart during each trial. The foot position of the par-
ticipants wasmarked on the forceplate to ensure that they returned to
the same foot position in every trial. Participants were instructed to
focus during the standing trial on a visual target placed at eye level
approximately 3 m in front of them. A practice trial on ground level
as performed first to allow participants to become familiarized with
he procedures and remove any potential first trial effects (Adkin et
l., 2000). After the initial practice trial, participants performed a 2min
tanding trial in the normal condition, followed by the reduced threat,
edium threat and high threat condition, with a few minutes of
eated rest in between each standing condition. The effect of pos-
ural threat on postural control is known to be influenced by order,
ith greater postural changes observed when participants stand in
ncreasingly threatening, compared to less threatening, conditions
Adkin et al., 2000). Based on this knowledge, the four conditions
Table 1. Baseline subject characteristics
Patients
(N14)
eneral information
Age (years) 68.1 (5
Number of women (%) 3 (21
Height (cm) 172.8 (8
Weight (kg) 82.1 (1
Fallers 2 (14
Fear of falling 1 (7%
Fear of heights 6 (43
Trait-anxiety score 30.0 (6
Mini mental state examination 29.0 (1
Frontal assessment battery 16.4 (1
Duration of disease (years) 5.6 (2
Hoehn and Yahr score 2.5 (0
UPDRS motor examination score 23.9 (7
arkinson medication
Levodopa/carbidopa 13 (93
Ropinirole 1 (7%
Pramipexole 6 (43
Rasagiline 4 (29
Amantadine 2 (14
Data are displayed as mean (standard deviation) or as the number o
able 2. Demographic data PD patients
PD
patient
Age
(years)
Fear of
heights
Fear
of
falling
Faller ABC
scale
score
1 71 Yes No No 51
2 64 No No No 79
3 75 No No No 100
4 69 Yes No No 97
5 63 No No No 85
6 74 No No No 89
7 62 No No No 99
8 62 Yes No No 96
9 70 Yes Yes Yes 61
10 63 No No No 99
11 76 No No No 98
12 75 Yes No No 99
13 66 Yes No No 84
14 64 No No Yes 91
Maximum ABC scale score is 100, maximum trait anxiety score is
s 5.ere presented in a fixed order across participants, to maximize the
otential effect of threat, and thus provide the greatest opportunity to
bserve potential interactions with PD. Randomization would likely
ullify the effect of threat on postural control, making potential inter-
ctions between groups and threat more difficult to discern.
Measurements
Several questionnaires were used to assess levels of anxiety, fear
and balance confidence prior to testing, as well as before and after
each standing trial. Prior to performing the practice trial, partici-
pants filled in the trait section of the state and trait anxiety inven-
tory which uses a 4 point scale (from 1 (almost never) to 4 (almost
always)) to rate 20 different statements referring to individual
differences in the frequency and intensity with which anxiety man-
Controls Significance
(N16)
68.8 (5.0) NS (P.749)
7 (44%)
171.1 (9.0) NS (P.599)
71.9 (11.7) S (P.046)
0 (0%)
1 (6%)
3 (19%)
27.9 (6.0) NS (P.362)
29.1 (1.1) NS (P.743)
16.7 (1.3) NS (P.557)
(percentage between parentheses). NS, not significant; S, significant.
y
Duration
(years)
UPDRS
motor
score
Hoehn
and
Yahr
Parkinson medication
(levodopa equivalent
dose)
2.5 31 3 850 mg
5 18 2 1050 mg
6 37 3 300 mg
7 23 2 526 mg
9 17 2.5 1301 mg
2 26 2.5 200 mg
2 6 2 900 mg
3 23 2.5 500 mg
8 35 3 1100 mg
10.5 24 2 801 mg
2 22 2.5 526 mg
6 24 2 876 mg
6 28 2.5 1000 mg
9 20 3 300 mg
imum UPDRS motor score is 108, maximum Hoehn and Yahr score.3)
%)
.2)
4.9)
%)
)
%)
.1)
.0)
.7)
.9)
.4)
.8)
%)
)
%)
%)
%)Trait
anxiet
score
34
33
27
27
26
37
29
30
46
23
25
29
31
23
80, max
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E. P. Pasman et al. / Neuroscience 177 (2011) 283–291286ifests itself over time (Barnes et al., 2002). Prior to each standing
trial, participants rated how confident they were that they could
maintain their balance and avoid a fall during the upcoming bal-
ance task on a scale from 0% (not confident at all) to 100%
(completely confident). After each standing trial, participants rated
how stable and how fearful of falling they felt during the trial, both
on a scale from 0% (i.e. not stable/not fearful of falling) to 100%
(i.e. completely stable/fearful of falling) (Hauck et al., 2008). After
each trial, participants also filled in the state anxiety questionnaire,
which consists of 16 items rated on a scale from 1 (didn’t feel at
all) to 9 (felt this extremely) (Hauck et al., 2008) and the positive
and negative affect schedule-expanded form (PANAS-X) fear sub-
scale, where participants indicate the extent to which they feel (on
a scale from 1 (not at all) to 5 (extremely)) about six words that
describe different feelings and emotions (Watson and Clark,
1994).
During the trials, participants’ galvanic skin response (GSR)
and ground reaction forces and moments were also recorded.
GSR, a measure of physiological arousal, was recorded from
electrodes placed on the thenar and hypothenar eminence of the
participant’s non-dominant hand (Critchley, 2002). GSRmeasures
were recorded at a sampling rate of 1 kHz and were smoothed
off-line at a time constant of 0.2 s, prior to calculating the mean
GSR over the entire 120 s trial. The mean GSR for each trial was
normalized to the values recorded during the practice trial. Ground
reaction forces and moments measured from the forceplate on
which the participants stood were sampled at 100 Hz and low pass
filtered offline using a 5 Hz dual-pass Butterworth filter, prior to
calculating the COP in the AP and ML direction. The mean COP
in the AP and ML directions was determined and removed from
the signal prior to calculating the root mean square (RMS) and the
mean power of frequency (MPF) of COP displacements.
Statistical analysis
Independent T-tests were performed to compare baseline clinical
measures between controls and PD patients (Table 1). All depen-
dent measures were analyzed using a 23 between and within
subject analysis of variance with threat (normal, medium and high)
and group (controls and PD) as independent variables. Assump-
tions of normality and homogeneity of variances were examined
and met across most dependent measures, variables and exper-
imental conditions. Tests of assumptions were based on inspec-
tion of histograms and box-plots, and statistical tests of homoge-
neity. Levine’s tests demonstrated equality of variances across
groups for all measures (P0.05). In the few cases where Box’s
M tests of equality of co-variance matrices (P0.001) and/or
Mauchly’s tests of sphericity (P0.05) were significant, the Green-
house–Gueisser  statistic was used. An overall 0.05 was used
or all statistical comparisons. In cases of significant main and
nteraction effects, post hoc comparisons were performed after
djusting for multiple comparisons using a Bonferroni correction
adjusted level of significance0.017). Differences between high
hreat and normal threat conditions were also calculated and used
o examine associations between changes in psycho-social and
SR measures with changes in postural control using Pearson
roduct moment correlations (P0.05).
RESULTS
Manipulation of postural threat via changes in surface
height resulted in significant changes in physiological and
psychosocial indicators of arousal, anxiety and fear in both
groups. There was a significant main effect of threat on the
mean GSR level (F(1.664,46.580)18.696, P0.001), with
igher GSR levels observed in the medium and high threat
onditions compared to the normal condition. A significant
ain effect of threat was observed for state-anxietyF(2,56)10.626, P0.001), fear (F(1.185,33.191)13.382,
P0.001), fear of falling (F(1.972,55.229)5.10, P0.010),
alance confidence (F(1.275,35.713)5.324, P0.02) and
erceived stability (F(2,56)9.626, P0.001). Significantly
higher scores of state-anxiety and fear were observed in
the high threat condition compared to the normal and
medium threat condition. Fear of falling for the high threat
condition was significantly higher than for the normal con-
dition. Balance confidence was significantly lower in the
medium and high threat condition compared to the normal
condition. Perceived stability was also significantly lower in
the high threat condition compared to the normal condition,
and medium threat condition. There was no significant
main effect of group or interaction between threat and
group on GSR or psychosocial measures (Fig. 1).
Postural threat also had a significant influence on COP
easures in both groups (Fig. 2). There was a significant
ain effect of threat on the mean position of AP-COP
F(1.579,44.202)54.653, P0.001). The mean position of
P-COP was shifted significantly backwards (away from
he edge) in the medium and high threat conditions com-
ared to the normal condition, and in the high threat com-
ared to medium threat condition. There was also a sig-
ificant main effect of threat on the MPF of COP in the
P (F(1.515,42.425)14.053, P0.001) and ML direction
(F(2,56)3.507, P0.037). AP-MPF in the medium and
high threat conditions was significantly higher than in the
normal condition, while there was a trend towards higher
ML-MPF in the high threat condition than in the normal
condition (P0.031). There was no significant main effect
of threat on RMS of COP in the AP (F(2,56)1.494,
P0.233) or ML direction (F(1.914,53.592)0.058, P0.938).
or all COP measures there was no main effect of group or
nteraction between threat and group (Fig. 3).
Across both groups, there was a significant positive
orrelation between changes in total anxiety and changes
n MPF of COP in the AP (r.391, P0.032) and ML
irections (r.424, P0.019). Likewise, there was a sig-
nificant positive correlation between changes in the
PANAS-X fear subscale and changes in RMS of COP in
the AP direction (r.441, P0.015). No psychosocial or
GSR changes were correlated to changes in mean COP
position (P0.05).
DISCUSSION
Postural threat influenced balance control in both PD
patients and controls
The aim of this study was to examine whether patients and
controls responded similarly to increases in postural threat.
Brown and colleagues investigated whether PD patients
alter their postural control of quiet standing in reaction to
changes in environmental context (postural threat). They
measured quiet standing in a low threat condition (0.6 m
height with a wooden platform in front of the hydraulic lift to
provide an opportunity to step forward) and a high threat
condition (0.6 m height with the wooden platform re-
moved). The results showed that PD patients manifested
no changes in postural control during quiet standing with
s
i resent si
(
E. P. Pasman et al. / Neuroscience 177 (2011) 283–291 287heightened postural threat, while controls showed a signif-
icant posterior shift of mean position of AP-COP and sig-
nificant reduction in RMS amplitude of COP displace-
ments. The authors concluded that PD patients have def-
icits in context-dependent regulation of quiet standing
(Brown et al., 2007). However, these results are inconsis-
tent with the current observations of a posterior shift in
mean position of AP-COP and increased MPF in the AP
and ML direction in both PD patients and controls. Indeed,
the current results indicate that PD patients can react to
changes in threat level similar to controls. Although patient
characteristics, including mean disease duration, the
range in UPDRS motor scores and medications were very
similar between the current study and that of Brown and
colleagues, other differences are noteworthy. One impor-
tant difference between the studies is that Brown and
colleagues actually used step restriction, instead of sur-
face height, to increase postural threat. It has been shown
that surface height influences balance control during quiet
stance independent of step restriction (Carpenter et al.,
1999). Furthermore, Brown and colleagues did not mea-
sure psychosocial or physiological indicators of anxiety or
fear, in order to confirm the extent to which the manipula-
tion of step restriction leads to changes in fear or anxiety.
Fig. 1. Physiological and psychosocial anxiety measures. Bar graphs o
ubscale score (B), fear of falling (C), state-anxiety questionnaire sc
ndicating controls and white bars indicating PD patients. Asterisks rep
P0.017).In contrast, the current study demonstrated that the ma-nipulations of surface height were accompanied by signif-
icant changes in self-reported ratings of state anxiety, fear,
balance confidence and perceived stability in both PD
patients and controls. Furthermore changes in state anxi-
ety and fear were found to be significantly correlated with
changes in postural control across groups. Another impor-
tant difference between studies was the time period used
to collect COP measures during quiet stance. Brown and
colleagues used a sampling duration of only 15 s, which is
possibly too short to record reliable amplitude and fre-
quency measures of postural control during quiet stance
(Carpenter et al., 2001b). In contrast, the current study
sampled COP measures over 120 s of quiet stance, which
exceeds the minimum time period required to ensure reli-
able and accurate measures of amplitude and frequency of
COP displacements (Carpenter et al., 2001b).
The significant relationships observed between fear
and anxiety on postural control adds further support to the
proposed neural link between areas of the brain controlling
emotion, and areas responsible for balance control in hu-
mans (Balaban and Thayer, 2001). In particular, the
amygdala and associated limbic structures are central to
the acquisition, modulation and expression of emotions,
such as fear and anxiety, and have widespread efferent
tion means and standard errors of mean GSR level (A), PANAS-X fear
balance confidence (E) and perceived stability (F), with black bars
gnificant differences in post-hoc comparisons between levels of threatf popula
ore (D),connections to areas involved in posture, including vestib-
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E. P. Pasman et al. / Neuroscience 177 (2011) 283–291288ular nuclei, the reticular formation, and nuclei within the
basal ganglia and nucleus accumbens (Cardinal et al.,
2002; Balaban and Thayer, 2001).
Due to study limitations, the current results are unable to
larify the basal ganglia’s role in mediating the effects of
nxiety and fear on postural control. One such limitation was
hat participants were tested after they had taken their normal
oses of Parkinson medication. Although dopaminergic med-
cation generally has little effect on improving postural control,
articularly during quiet stance (Rocchi et al., 2002; Bloem
nd Bhatia, 2004; Bloem et al., 1996), it may offer significant
mprovements to anxiety and emotional processing deficits in
D (Witjas et al., 2002; Maricle et al., 1995a,b; Tessitore et
l., 2002). Therefore, future studies need to include PD pa-
ients both ON medication (ideally after a supramaximal
evodopa dose, to ensure an optimal and consistent ON
hase throughout the experiment) and OFF medication, in
rder to ascertain the basal ganglia’s role in mediating anxi-
ty-related changes in postural control.
Another limitation of the study was that subjects were
xcluded on the basis of having a history of anxiety disorders,
xtreme fear of heights, and/or treatment with anti-anxiety
edications. The exclusion of those with anxiety disorders
nd extreme fear of heights was justified on ethical grounds,
o avoid placing patients in threatening conditions that could
otentially trigger an anxiety attack or phobic reactions. Sub-
ects taking anti-anxiety medication were excluded for meth-
dological reasons as the medication would likely mask any
ormal anxiety response to the threat of standing on elevated
Fig. 2. Single subject COP data. Single subject recordings of COP dis
medium threat (middle) and high threat (right) conditions. The illustrat
the normal threat condition with negative values on the x and y axis rurfaces. However, we realize that this may have impacted tur ability to detect differences between groups, and thus,
imited any insight into how the basal ganglia may contribute
o anxiety-related effects on postural control. It also limits the
bility to generalize the current results to the significant num-
er of patients that suffer from clinical and non-clinical anxiety
Stein et al., 1990; Menza et al., 1993; Aarsland et al., 1999;
ulisevsky et al., 2008). Therefore, further studies should be
one to investigate the influence of anxiety and fear on the
ostural control of PD patients with known anxiety.
A third limitation is that subjects included in this
tudy were relatively well functioning and showed little
vidence of postural deficits during clinical examination
nd fall history. Although nine of the subjects scored
bnormally on the clinical postural test, only two had a
istory of falls, and both of these subjects responded to
he changes in height in the same way as the others.
rrespectively, there are still questions regarding whether
ubjects with more severe motor and postural deficits
ould show greater differences in postural control com-
ared to controls, and whether they may respond differ-
ntly to changes in postural threat.
o main effect of PD on postural control measures
n this study, no significant differences were observed
etween PD patients and controls in terms of amplitude,
requency, or mean position of COP. This result provides
urther evidence in support of prior studies that have re-
orted no significant differences in COP measures be-
ts during 120 s standing trials under conditions of normal threat (left),
ses, origin of the axes have been normalized to the mean position of
ing leftward and backward directions respectively.placemenween PD patients and controls during quiet stance (Schi-
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E. P. Pasman et al. / Neuroscience 177 (2011) 283–291 289eppati and Nardone, 1991; Termoz et al., 2008). These
ndings contradict others that have reported the effects of
D on COP amplitude (Horak et al., 1992; Mitchell et al.,
995; Contin et al., 1996; Rocchi et al., 2002; Maurer et
l., 2003; Nardone and Schieppati, 2006; Błaszczyk et
l., 2007), frequency, (Rocchi et al., 2002; Maurer et al.,
003), or mean position of COP (Schieppati and Nar-
one, 1991; Błaszczyk et al., 2007; Termoz et al., 2008).
ifferences between the current study and previous work
re not likely related to differences in disease severity of
atients, as the UPDRS and Hoehn and Yahr scores were
imilar to those reported in prior studies. Therefore, likely
ources of variation may be attributed to differences in
xperimental protocols, including instruction, sample dura-
ion and analysis, timing and dose of medication, or the
resence of other co-morbidities (including anxiety symp-
oms).
elevance of the findings to a clinical setting
espite the limitations described above, the results of
his study show that the postural control of quiet stand-
ng in healthy elderly control subjects and PD patients on
edication is equally susceptible to the influence of
nxiety. Given the high prevalence of anxiety and fear of
alling in PD patients, it should be considered a factor
Fig. 3. COP summary measures. Bar graphs of population means and
(D) and RMS (E) of COP, with black bars indicating controls and wh
post-hoc comparisons between levels of threat (P0.017).hen interpreting balance assessments in this patientopulation. This should be done especially if compari-
ons are made with healthy elderly control subjects, in
hom the prevalence of anxiety and fear is lower than in
D patients.
Evidence that sources of anxiety can influence balance
n older healthy adults (Carpenter et al., 1999, 2006; Brown
t al., 2006; Geh et al., 2010), as well as PD patients, also
ighlights the need for clinicians to account for other po-
ential sources of anxiety or fear that could either mask or
imic a potential balance deficit. Potential sources of anx-
ety include anxiogenic or anxiolytic medications, clinical or
on-clinical anxiety disorders, and social anxiety related to
he prospect of being negatively evaluated by the clinician
Geh et al., 2010).
CONCLUSION
In summary, the results of this study indicate that static
balance in PD patients and healthy elderly controls is
equally susceptible to the influence of anxiety. Future
studies could further address this issue by including
more severely affected patients both ON and OFF do-
paminergic medication, more anxious patients, or by
using dynamic measures of balance.
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